MedTrace Logo

A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer

NCT02958852 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2025-09-10

No results posted yet for this study

Summary

A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment with Focus on Mechanisms of Resistance to Endocrine Treatment (fulvestrant/aromatase inhibitors) in Patients With Advanced Breast Cancer.

Conditions

Interventions

DRUG

Letrozole

Daily orally

DRUG

Letrozole and atorvastatin

Daily orally

DRUG

Fulvestrant

Fulvestrant will be used as second line treatment upon progression on first line treatment with letrozole +/- atorvastatin.

Sponsors & Collaborators

  • South Sweden Breast Cancer Group

    collaborator UNKNOWN

  • Lund University Hospital

    lead OTHER

Principal Investigators

  • Signe Borgquist, MD, PhD · Lund University Hospital, Department of Oncology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-02
Primary Completion
2025-01-02
Completion
2025-01-15

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02958852 on ClinicalTrials.gov